Full-Time

Associate Director

Global Real-World Evidence, Oncology

Posted on 8/5/2026

Deadline 8/23/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

+ Long-term incentive program

Raritan, NJ, USA

Hybrid

Hybrid work is required in Raritan, New Jersey; approximately 10% travel is required, primarily domestic with some international travel.

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Python
SAS
Data Visualization
Data Science
R
Electronic Health Records (EHR)
Biostatistics
Data Analysis

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • An advanced degree in epidemiology, pharmacoepidemiology, health economics and outcomes research, public health, biostatistics, health policy, health services research, or a related field is required.
  • A minimum of 5 years of relevant experience in the pharmaceutical, biotechnology, consulting, academic, or healthcare environment is required, with experience in real-world evidence, epidemiology, outcomes research, medical affairs, market access, or related functions.
  • Demonstrated experience supporting the design and execution of real-world evidence studies, including observational studies, retrospective database analyses, evidence synthesis, protocol development, analytic planning, interpretation of results, and scientific dissemination.
  • Strong working knowledge of real-world data sources and fit-for-purpose real-world evidence methods is required, including claims databases, electronic health records, registries, chart reviews, and other healthcare data sources.
  • Ability to provide methodological input on observational study design, analytic approaches, bias mitigation, data interpretation, and communication of real-world evidence findings to technical and non-technical audiences is required.
  • Experience collaborating with programmers, statisticians, epidemiologists, real-world evidence researchers, cross-functional partners, and external vendors to execute data-driven research projects is required.
  • Strong project management skills are required, including the ability to manage timelines, coordinate deliverables, track decisions and actions, support governance processes, and drive execution in a matrixed global environment.
  • Strong communication, presentation, and scientific writing skills are required, with the ability to translate complex research concepts and data-driven insights into clear messages for internal and external stakeholders.
  • Experience contributing to publications, congress presentations, internal evidence-generation deliverables, or other scientific communication outputs is required.
Responsibilities
  • Support the Global Real-World Evidence Disease Lead in developing and maintaining Integrated Evidence Generation Plans and long-range Worldwide Real-World Evidence Roadmaps for assigned disease areas and assets.
  • Drive high-quality execution of priority real-world evidence studies and evidence-generation projects, ensuring timely delivery, scientific rigor, operational excellence, and appropriate interpretation and dissemination of study outputs.
  • Collaborate with real-world evidence researchers, programmers, cross-functional partners, regional and local evidence-generation teams, and external vendors to translate study concepts into protocols, analyses, deliverables, publications, and other evidence-dissemination materials.
  • Support the Disease Lead in global and regional stakeholder management across cross-functional workstreams, real-world evidence working groups, Evidence Labs, and project execution forums.
  • Serve as a methodology subject matter expert in assigned cross-functional workstreams, providing scientific input on real-world data sources, observational study designs, analytic approaches, fit-for-purpose evidence methods, and best practices.
  • Analyze, interpret, and synthesize real-world data, literature, competitive evidence, and stakeholder insights to inform evidence-gap assessments, strategic trade-off discussions, urgent business requests, and cross-functional decision-making.
  • Contribute to real-world evidence operational governance, standards, processes, and operating models by supporting prioritization, resource planning, deliverable tracking, review processes, vendor oversight, and consistency across disease- and asset-level activities.
  • Ensure assigned real-world evidence activities comply with applicable regulatory, legal, privacy, publication, and commercial requirements while upholding scientific integrity, responsible communication, and evidence dissemination.
Desired Qualifications
  • A PhD is preferred.
  • Experience with global, multi-country real-world evidence studies is preferred.
  • Hands-on experience with SAS, R, Python, or other statistical programming tools is preferred.
  • Oncology experience is strongly preferred.
  • Working knowledge of the global healthcare, reimbursement, payer, medical affairs, and evidence-generation environment is preferred, particularly as it relates to oncology product strategy and stakeholder evidence needs.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales hit $25.3 billion, and guidance rose to $101.1 billion.
  • Tremfya surged 72.5% to $2 billion, proving the immunology replacement strategy works.
  • August 21, 2026 TECVAYLI-daratumumab approval and MONARCH QUEST 3 clearance expand pipelines.

What critics are saying

  • July 2026 talc settlement needs 95% claimant approval; failure reopens 76,000 claims.
  • Stelara biosimilars keep crushing legacy revenue, and replacement drugs must sustain 2027 growth.
  • MedTech growth lagged Q2 expectations; Intuitive Surgical and Medtronic intensify hospital-buying competition.

What makes Johnson & Johnson unique

  • J&J spans pharmaceuticals, MedTech, and cash-generating scale after Kenvue’s 2023 spinout.
  • Tremfya, Darzalex, Carvykti, and Tecvayli offset Stelara’s 55% Q2 decline.
  • AAA balance sheet and 64-year dividend streak signal resilience through patent cliffs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 21st, 2026
J&J's TECVAYLI plus daratumumab approved in Europe for relapsed/refractory multiple myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI (teclistamab) combined with daratumumab for treating adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The approval, based on Phase 3 data, makes this immunotherapy doublet available as early as second-line treatment. The combination demonstrated statistically significant improvements in progression-free and overall survival versus standard care regimens. The drugs work complementarily, with daratumumab modulating the immune system to enhance T-cell fitness and activation, amplifying teclistamab's ability to kill myeloma cells. Over 90% of patients who were progression-free at six months remained so at three years. The treatment offers an off-the-shelf, steroid-sparing immunotherapy option for patients who often experience shorter remissions with each subsequent therapy line.

Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

INACTIVE